))
Ep. 61 - Vas Narasimhan: How New Data Fit Novartis’ Growth Plan
Manage episode 421333597 series 3571902
Content provided by BioCentury. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioCentury or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Differentiating on tolerability, raising the bar for efficacy and concentrating small molecule development on indications with minimal IRA exposure are all pieces of Novartis CEO Vasant Narasimhan’s strategy to break into the top pharmas by U.S. sales. Two data readouts this week — one for CML drug Scemblix at ASCO and one for inflammatory disease therapy remibrutinib at the EAACI Congress — may tee up two launches to advance that goal through a strategy focused on prioritizing blockbuster-bound programs. Narasimhan discusses the readouts with Editor in Chief Simone Fishburn on a Special Edition of The BioCentury Show.
View full story: https://www.biocentury.com/article/652562
#biotech #biopharma #pharma #lifescience
00:00 - Intro
01:12 - CML Data
09:34 - Endpoints, Approval Pathway
13:00 – Remibrutinib
24:07 – IRA, Radioligands
Chapters
1. Ep. 61 - Vas Narasimhan: How New Data Fit Novartis’ Growth Plan (00:00:00)
2. CML Data (00:01:12)
3. Endpoints, Approval Pathway (00:09:34)
4. Remibrutinib (00:13:00)
5. IRA, Radioligands (00:24:07)
13 episodes
Share
